间日疟原虫入侵红细胞的相关蛋白研究进展

摘要/Abstract

摘要：

基于疟原虫入侵途径的多样化以及红细胞表面受体的多样性,间日疟原虫入侵红细胞的过程呈现高度的种特异性。寻找参与疟原虫入侵红细胞的相关分子,探索其入侵机制是疟疾研究领域的重点。间日疟原虫全基因组测序的完成,为从分子水平探索间日疟原虫的入侵机制和疟疾候选疫苗的研究提供了新的研究方法。本文通过达菲结合蛋白、网织红细胞结合蛋白、间日疟原虫色氨酸富集抗原等几种重要的入侵蛋白,对间日疟原虫入侵红细胞分子机制的研究进展作一综述。

关键词: 间日疟原虫, 红细胞入侵, 分子机制

Abstract:

Different Plasmodium species utilize different invasion pathways and specific sets of ligand-receptor interactions to exert distinct invasion behaviors of merozoites. Most studies on host cell invasion by Plasmodium have concentrated on invasion of erythrocytes. With completion of the whole-genome sequencing of P. vivax, proteins involved in erythrocyte invasion, such as the duffy binding protein, the reticulocyte binding protein, and tryptophan-rich antigens, have been identified. This review summarizes the role of these proteins in erythrocyte invasion.

Key words: Plasmodium vivax, Erythrocyte invasion, Molecular mechanism

中图分类号:

R382.311

张馨心, 楚瑞林, 玄英花, 程洋. 间日疟原虫入侵红细胞的相关蛋白研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2018, 36(2): 161-165.

Xin-xin ZHANG, Rui-lin CHU, Ying-hua XUAN, Yang CHENG. Research progress on proteins associated with Plasmodium vivax invasion of erythrocytes[J]. Chinese Journal of Parasitology and Parasitic Diseases, 2018, 36(2): 161-165.

图/表 1

参考文献 50

[1]	World Health Organization.World malaria report 2017[R]. Geneva: World Health Organization, 2017.
[2]	Guerra CA, Howes RE, Patil AP, et al. The international limits and population at risk of Plasmodium vivax transmission in 2009[J]. PLoS Negl Trop Dis, 2010, 4(8): e774.
[3]	张丽, 丰俊, 张少森, 等. 2016年全国疟疾疫情分析[J]. 中国寄生虫学与寄生虫病杂志, 2017, 35(6): 515-519.
[4]	李奔福, 蔺应学, 郭祥瑞, 等. 中缅边境疟疾流行情况调查[J]. 中国寄生虫学与寄生虫病杂志, 2015, 33(4): 261-263.
[5]	张冬梅, 潘卫庆. 我国疟疾疫苗研究进展及前景[J]. 中国寄生虫学与寄生虫病杂志, 2009, 27(5): 390-393.
[6]	徐超, 魏庆宽, 李瑾, 等. 境外输入性恶性疟原虫抗药性相关基因突变的检测[J]. 中国寄生虫学与寄生虫病杂志, 2016, 34(6): 482-488.
[7]	Michon P, Fraser T, Adams JH.Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding protein[J]. Infect Immun, 2000, 68(6): 3164-3171.
[8]	Ceravolo IP, Souza-Silva FA, Fontes CJ, et al. Inhibitory properties of the antibody response to Plasmodium vivax Duffy binding protein in an area with unstable malaria transmission[J]. Scand J Immunol, 2008, 67(3): 270-278.
[9]	King CL, Michon P, Shakri AR, et al. Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection[J]. Proc Natl Acad Sci USA, 2008, 105(24): 8363-8368.
[10]	Ntumngia FB, Richard TL, Menezes TLD, et al. A novel erythrocyte binding protein of Plasmodium vivax suggests an alternate invasion pathway into Duffy-positive reticulocytes[J]. MBio, 2016, 7(4).
[11]	Gupta ED, Anand G, Singh H, et al. Naturally acquired human antibodies against reticulocyte-binding domains of Plasmodium vivax proteins, PvRBP2c and PvRBP1a, exhibit binding-inhibitory activity[J]. J Infect Dis, 2017, 215(10): 1558-1568.
[12]	Zeeshan M, Tyagi RK, Tyagi K, et al. Host-parasite interaction: selective Pv-fam-a family proteins of Plasmodium vivax bind to a restricted number of human erythrocyte receptors[J]. J Infect Dis, 2015, 211(7): 1111-1120.
[13]	Alam MS, Zeeshan M, Mittra P, et al. Receptor specific binding regions of Plasmodium vivax tryptophan rich antigens and parasite growth inhibition activity of PvTRAg35.2[J]. Microbes Infect, 2016, 18(9): 550-558.
[14]	Cheng Y, Lu F, Wang B, et al. Plasmodium vivax GPI-anchored micronemal antigen(PvGAMA) binds human erythrocytes independent of Duffy antigen status[J]. Sci Rep, 2016, 6(6).
[15]	Baquero LA, Moreno-Pérez DA, Garzón-Ospina D, et al. PvGAMA reticulocyte binding activity: predicting conserved functional regions by natural selection analysis[J]. Parasit Vectors, 2017, 10(1): 251.
[16]	Cutbush M, Mollison PL.The Duffy blood group system[J]. Heredity (Edinb), 1950, 4(3): 383-389.
[17]	Miller LH, Mason SJ, Dvorak JA, et al. Erythrocyte receptors for(Plasmodium knowlesi) malaria: Duffy blood group determinants[J]. Science, 1975, 189(4202): 561-563.
[18]	Chitnis CE, Chaudhuri A, Horuk R, et al. The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi malarial parasites to erythrocytes[J]. J Exp Med, 1996, 184(4): 1531-1536.
[19]	Chitnis CE, Sharma A.Targeting the Plasmodium vivax Duffy-binding protein[J]. Trends Parasitol, 2008, 24(1): 29-34.
[20]	Carlton JM, Adams JH, Silva JC, et al. Comparative genomics of the neglected human malaria parasite Plasmodium vivax[J]. Nature, 2008, 455(7214): 757-763.
[21]	Batchelor JD, Malpede BM, Omattage NS, et al. Red blood cell invasion by Plasmodium vivax: structural basis for DBP engagement of DARC[J]. PLoS Pathog, 2014, 10(1): e1003869.
[22]	Grimberg BT, Udomsangpetch R, Xainli J, et al. Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein[J]. PLoS Med, 2007, 4(12): e337.
[23]	Woolley IJ, Hotmire KA, Sramkoski RM, et al. Differential expression of the Duffy antigen receptor for chemokines according to RBC age and FY genotype[J]. Transfusion, 2000, 40(8): 949-953.
[24]	Gunalan K, Lo E, Hostetler JB, et al. Role of Plasmodium vivax Duffy-binding protein 1 in invasion of Duffy-null Africans[J]. Proc Natl Acad Sci USA, 2016, 113(22): 6271-6276.
[25]	Hester J, Chan ER, Menard D, et al. De novo assembly of a field isolate genome reveals novel Plasmodium vivax erythrocyte invasion genes[J]. PLoS Negl Trop Dis, 2013, 7(12): e2569.
[26]	Neafsey DE, Galinsky K, Jiang RH, et al. The malaria parasite Plasmodium vivax exhibits greater genetic diversity than Plasmodium falciparum[J]. Nat Genet, 2012, 44(9): 1046-1050.
[27]	Urquiza M, Patarroyo MA, Marí V, et al. Identification and polymorphism of Plasmodium vivax RBP-1 peptides which bind specifically to reticulocytes[J]. Peptides, 2002, 23(12): 2265-2277.
[28]	Galinski MR, Barnwell JW.Plasmodium vivax: merozoites, invasion of reticulocytes and considerations for malaria vaccine development[J]. Parasitol Today (Regul Ed), 1996, 12(1): 20-29.
[29]	Han JH, Lee SK, Wang B, et al. Identification of a reticulocyte-specific binding domain of Plasmodium vivax reticulocyte-binding protein 1 that is homologous to the PfRh4 erythrocyte-binding domain[J]. Sci Rep, 2016, 6: 26993.
[30]	Cantor EM, Lombo TB, Cepeda A, et al. Plasmodium vivax: functional analysis of a highly conserved PvRBP-1 protein region[J]. Mol Biochem Parasitol, 2001, 117(2): 229-234.
[31]	Burns JM Jr, Adeeku EK, Dunn PD.Protective immunization with a novel membrane protein of Plasmodium yoelii-infected erythrocytes[J]. Infect Immun, 1999, 67(2): 675-680.
[32]	Burns JM, Adeeku EK, Belk CC, et al. An unusual tryptophan-rich domain characterizes two secreted antigens of Plasmodium yoelii-infected erythrocytes[J]. Mol Biochem Parasitol, 2000, 110(1): 11-21.
[33]	Curtidor H, Ocampo M, Rodríguez LE, et al. Plasmodium falciparum TryThrA antigen synthetic peptides block in vitro merozoite invasion to erythrocytes[J]. Biochem Biophys Res Commun, 2006, 339(3): 888-896.
[34]	Wang B, Lu F, Cheng Y, et al. Immunoprofiling of the tryptophan-rich antigen family in Plasmodium vivax[J]. Infect Immun, 2015, 83(8): 3083-3095.
[35]	Tyagi RK, Sharma YD.Erythrocyte binding activity displayed by a selective group of Plasmodium vivax tryptophan rich antigens is inhibited by patients′ antibodies[J]. PLoS One, 2012, 7(12): e50754.
[36]	Zeeshan M, Tyagi K, Sharma YD.CD4+ T cell response correlates with naturally acquired antibodies against Plasmodium vivax tryptophan-rich antigens[J]. Infect Immun, 2015, 83(5): 2018-2029.
[37]	Rathore S, Dass S, Kandari D, et al. Basigin interacts with Plasmodium vivax tryptophan-rich antigen PvTRAg38 as a second erythrocyte receptor to promote parasite growth[J]. J Biol Chem, 2017, 292(2): 462-476.
[38]	Alam MS, Choudhary V, Zeeshan M, et al. Interaction of Plasmodium vivax tryptophan-rich antigen PvTRAg38 with band 3 on human erythrocyte surface facilitates parasite growth[J]. J Biol Chem, 2015, 290(33): 20257-20272.
[39]	Tyagi K, Hossain ME, Thakur V, et al. Plasmodium vivax tryptophan rich antigen PvTRAg36.6 interacts with PvETRAMP and PvTRAg56.6 interacts with PvMSP7 during erythrocytic stages of the parasite[J]. PLoS One, 2016, 11(3): e0151065.
[40]	Gilson PR, Nebl T, Vukcevic D, et al. Identification and stoichiometry of glycosylphosphatidylinositol-anchored membrane proteins of the human malaria parasite Plasmodium falciparum[J]. Mol Cell Proteomics, 2006, 5(7): 1286-1299.
[41]	Arumugam TU, Takeo S, Yamasaki T, et al. Discovery of GAMA, a Plasmodium falciparum merozoite micronemal protein, as a novel blood-stage vaccine candidate antigen[J]. Infect Immun, 2011, 79(11): 4523-4532.
[42]	Babon JJ, Morgan WD, Kelly G, et al. Structural studies on Plasmodium vivax merozoite surface protein-1[J]. Mol Biochem Parasitol, 2007, 153(1): 31-40.
[43]	Cowman AF, Tonkin CJ, Tham WH, et al. The molecular basis of erythrocyte invasion by malaria parasites[J]. Cell Host Microbe, 2017, 22(2): 232-245.
[44]	O′Donnell RA, Saul A, Cowman AF, et al. Functional conservation of the malaria vaccine antigen MSP-119 across distantly related Plasmodium species[J]. Nat Med, 2000, 6(1): 91-95.
[45]	Cheng Y, Wang Y, Ito D, et al. The Plasmodium vivax merozoite surface protein 1 paralog is a novel erythrocyte-binding ligand of P. vivax[J]. Infect Immun, 2013, 81(5): 1585-1595.
[46]	Cowman AF, Healer J, Marapana D, et al. Malaria: biology and disease[J]. Cell, 2016, 167(3): 610-624.
[47]	Cheng Y, Shin EH, Lu F, et al. Antigenicity studies in humans and immunogenicity studies in mice: an MSP1P subdomain as a candidate for malaria vaccine development[J]. Microbes Infect, 2014, 16(5): 419-428.
[48]	Healer J, Murphy V, Hodder AN, et al. Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum[J]. Mol Microbiol, 2004, 52(1): 159-168.
[49]	Maskus DJ, Królik M, Bethke S, et al. Characterization of a novel inhibitory human monoclonal antibody directed against Plasmodium falciparum apical membrane antigen 1[J]. Sci Rep, 2016, 6: 39462.
[50]	Arévalo-Pinzón G, Bermúdez M, Hernández D, et al. Plasmodium vivax ligand-receptor interaction: PvAMA-1 domain I contains the minimal regions for specific interaction with CD71+ reticulocytes[J]. Sci Rep, 2017, 7(1): 9616.